01—Abstract
Summary
Summary of the 8-K filed December 6, 2024. Cited figures are marked; the original filing is the authoritative source.
On December 6, 2024, CVS Health announced the pricing of its cash tender offer for any and all of its outstanding 4.100%a Senior Notes due March 25, 2025 (CUSIP 126650CW8).
The offer, launched December 2, 2024, covers $950.1 millionb principal amount outstanding. Holders who validly tender by the 5:00 p.m. ET expiration on December 6 and are accepted for purchase will receive a total consideration of $998.22 per $1,000 principal amount, based on a 4.434% reference yield (the 3.875% UST due March 31, 2025 plus a 25 bps fixed spread), plus accrued and unpaid interest.
Settlement is expected December 11, 2024. The filing is a routine liability-management action. Because the notes mature in about three months, the tender effectively retires near-term debt, reducing the company's 2025 maturity wall while using cash on hand or new financing.
The 8-K does not disclose the funding source or the total amount of notes that will be tendered. The offer is subject to a financing condition and other general conditions described in the Offer to Purchase, and CVS may amend, extend, or terminate it before expiration. The filing does not indicate a material change to CVS's financial condition or guidance.
For investors, the key takeaways are the size of the refinancing effort relative to CVS's debt load and the price paid, which sits just under par. The results of the tender, including the final amount accepted, should be confirmed in a subsequent press release or filing.
02—Key points
Key Highlights
- CVS priced its cash tender offer for any and all of its 4.100% Senior Notes due March 25, 2025, covering $950.09 million in principal outstanding.
- Total consideration is $998.22 per $1,000 principal amount, set using a 4.434% reference yield (3.875% UST due 3/31/2025 plus a 25 bps fixed spread), as of 11:00 a.m. ET on December 6, 2024.
- Holders also receive accrued and unpaid interest from the last interest payment date through the settlement date.
- The early withdrawal deadline and expiration were both 5:00 p.m. ET on December 6, 2024; the expected settlement date is December 11, 2024.
- The offer has no minimum tender condition but is subject to a financing condition and other general conditions, and CVS may amend, extend, or terminate it at its discretion.
- Barclays Capital Inc. and Mizuho Securities USA LLC are Dealer Managers; D.F. King & Co., Inc. is the Tender and Information Agent.
- The filing covers only the Any and All Tender Offer and does not disclose the funding source or the final amount of notes accepted.
03—Questions
Frequently Asked Questions
What is CVS Health doing with these notes?
CVS is buying back, for cash, all of its outstanding 4.100% Senior Notes due March 25, 2025, through a tender offer. This retires debt that would otherwise mature in about three months.
How much will holders receive per note?
Holders whose notes are accepted will receive $998.22 per $1,000 principal amount, plus accrued and unpaid interest through the settlement date of December 11, 2024.
Is the tender offer guaranteed to complete?
No. The offer is subject to a financing condition and other general conditions in the Offer to Purchase, and CVS can amend, extend, or terminate it before the expiration time.
Does this change CVS's financial outlook?
The 8-K does not address guidance or financial results. Its impact is mainly on the timing of near-term debt repayment. Investors should check the final tender results and any financing disclosures for the funding source and the amount actually repurchased.
Why is the price just under par?
The notes have a 4.100% coupon, and the total consideration is based on a 4.434% reference yield on a short-dated Treasury plus a 25 bps spread. Since the notes are close to maturity, the price reflects the present value of the remaining payments at that yield, which is slightly below $1,000.
04—Continue